|
|
|
|
|
Cidofovir
drug data and news
Cidofovir drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Cidofovir | ||
| Brand Names/Synonyms | CDV; Cidofovir; Cidofovir Anhydrous; GS 0504; GS504; HPMPC; HSDB 7115; Vistide | ||
| Indication | For the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS) | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Cidofovir is a new anti-viral drug. It is classified as a nucleotide analogue and is active against herpes cytomegalovirus (CMV) retinitis infection. Most adults are infected with CMV. Cidofovir suppresses cytomegalovirus (CMV) replication by selective inhibition of viral DNA synthesis. Biochemical data support selective inhibition of CMV DNA polymerase by cidofovir diphosphate, the active intracellular metabolite of cidofovir. Cidofovir diphosphate inhibits herpesvirus polymerases at concentrations that are 8- to 600-fold lower than those needed to inhibit human cellular DNA polymerase alpha, beta, and gamma(1,2,3). Incorporation of cidofovir into the growing viral DNA chain results in reductions in the rate of viral DNA synthesis. | ||
| Mechanism Of Action | Cidofovir acts through the selective inhibition of viral DNA polymerase. | ||
| Cidofovir News (When available) |
CROI: Tenofovir and kidney toxicity - low rates seen, but some ... Feb 9, 2006 CROI: Tenofovir and kidney toxicity - low rates seen, but some ... 09 Feb 2006 Orf Virus Infection In Humans - NY, Illinois, California, And ... Jan 30, 2006 Monkeypox often affects lymph nodes Dec 7, 2005 Who Owns the Rights on Tamiflu: Rumsfeld To Profit From Bird Flu ... Oct 26, 2005 Progressive Multifocal Leukoencephalopathy in a Patient Treated ... Jul 27, 2005 Cancer drug may fight smallpox Jul 4, 2005 Recurrent Respiratory Papillomatosis with Lung Involvement Jun 15, 2005 Cancer drug may fight smallpox, study suggests 13 Sep 2002 Cidofovir Modulated Gene Expression in Recurrent Respiratory ... May 28, 2005 Recurrent Respiratory Papillomatosis with Lung Involvement Jun 15, 2005 Possible Cause of Tysabri-Related Deaths Proposed Jun 9, 2005 Progressive Multifocal Leukoencephalopathy in a Patient Treated ... Jun 9, 2005 Case of Fanconi syndrome caused by ddI reported May 12, 2005 | ||
| Dosage Forms | parenteral | ||
| Drug_Category | Anti-HIV Agents; Radiation-Sensitizing Agents; Antivirals; Antineoplastic Agents; ATC:J05AB12 | ||
| Absorption | 100% | ||
| Interactions |
Interactions for Cidofovir: Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine). Concomitant medications should be carefully assessed. Zidovudine should either be temporarily discontinued or decreased by 50% when coadministered with probenecid on the day of VISTIDE infusion. Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated. Such agents must be discontinued at least seven days prior to starting therapy with VISTIDE. | ||
| Toxicity | kidney damage, fall in the number of white blood cells, decrease platelets | ||
| Organisms Affected | Human immunodeficiency virus | ||
| Chemical IUPAC Name | [1-[(4-amino-2-oxo-1H-pyrimidin-1-yl)methyl]-2-hydroxy-ethoxy]methylphosphonicacid | ||
| Chemical Formula | C8H14N3O6P | ||
| Molecular Weight | 279.187 g/mol | ||
| Smiles String | C1=CN(C(=O)N=C1N)CC(CO)OCP(=O)(O)O | ||
| Melting Point | 480 °C | ||
| Water Solubility | =170 mg/mL at pH 6-8 | ||
| State | solid powder | ||
| LogP/Hphobicity | -3.3 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Not Available | ||
| Half Life | 2.4 to 3.2 hours | ||
| Protein Binding [%] | 6% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Cidofovir.html http://www.rxlist.com/cgi/generic2/cidofovir.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00148 | ||
| CAS Registry Number | 113852-37-2 | ||
| KEGG Compound ID | C06909 | ||
| PubChem ID | SID:196891 | ||
| PharmGKB ID | Not Available | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | Not Available |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |